RHHBY - Roche Holding AG

Other OTC - Other OTC Delayed Price. Currency in USD
31.53
+0.03 (+0.10%)
At close: 3:59PM EST
Stock chart is not supported by your current browser
Previous Close31.50
Open0.00
Bid0.00 x 0
Ask0.00 x 0
Day's Range0.00 - 0.00
52 Week Range
Volume0
Avg. Volume1,109,593
Market Cap215.847B
Beta (3Y Monthly)0.35
PE Ratio (TTM)20.54
EPS (TTM)1.54
Earnings DateN/A
Forward Dividend & Yield1.08 (3.44%)
Ex-Dividend Date2018-03-15
1y Target Est33.70
Trade prices are not sourced from all markets
  • The Wall Street Journal13 hours ago

    [$$] Roche Taps Genentech Chief to Lead Pharmaceuticals Division

    Roche Holding AG on Monday appointed Bill Anderson, head of its Genentech unit, to lead the company’s broader pharmaceuticals business, elevating an insider at a critical time for the division. The move follows the departure of company veteran Daniel O’Day, who is leaving the Swiss health care giant to be chief executive of Gilead Sciences Inc. Mr. Anderson, 52, joined Genentech in 2006 and held various sales and marketing roles before becoming head of the subsidiary last year. The management change comes as Roche Pharmaceuticals, the company’s largest division, confronts several challenges.

  • InvestorPlace22 hours ago

    Don’t Punish Gilead Stock for Doing Its Job

    In a turbulent year for Gilead Sciences (NASDAQ:GILD), the company recently generated headlines that will hopefully turn things around for GILD stock. Over the weekend, insider information pegged Roche Holdings (OTCMKTS:RHHBY) executive Daniel O’Day as its new CEO. O’Day is no stranger to the industry, having served as Roche Pharmaceuticals’ chief executive since June 3, 2016.

  • TheStreet.com19 hours ago

    Gilead Sciences Names Roche's O'Day as CEO and Chairman

    The California-based company's board on Monday announced that O'Day will become CEO and chairman effective March 1, 2019, replacing John Milligan, who previously said he would step down from his role as president and CEO and as a board member at the end of 2018. O'Day is currently CEO of Roche Pharmaceuticals, a position he has held since 2012. O'Day joined Roche back in 1987, taking on various roles in the U.S. before moving to Roche headquarters in Switzerland in 1998 and later to Japan, Denmark and eventually back to California.

  • Gilead Needs More Than a Steady Hand From Its New CEO
    Bloomberg19 hours ago

    Gilead Needs More Than a Steady Hand From Its New CEO

    With declining sales and an iffy pipeline, the stakes are higher for each deal. If O’Day chooses large or even mid-scale M&A, which would be a divergence from his recent focus on smaller deals at Roche, there will be a great deal of pressure to get it right.

  • Zacks20 hours ago

    Roche's Tecentriq Gets FDA Approval for First-Line NSCLC

    Roche's (RHHBY) Tecentriq in combination with Avastin obtains FDA nod for the initial treatment of NSCLC.

  • Barrons.com20 hours ago

    Gilead’s New CEO Might Boost Its Stock—Just Not Today

    Gilead’s stock has dropped more than 2% after the company named Roche Holdings’ Daniel O’Day as CEO.

  • Zacks23 hours ago

    Amgen (AMGN) Continues to Reward Shareholders, Ups Dividend

    Amgen (AMGN) hikes its quarterly dividend by 10%.

  • Reutersyesterday

    Gilead Sciences snares Roche veteran O'Day as CEO

    O'Day, now head of Roche's pharmaceuticals business, joined the company in 1987 and held various roles in the United States before moving in 1998 to headquarters in Basel, Switzerland. O'Day's hiring comes about four months after Gilead said in July that Chief Executive John Milligan and Chairman John Martin would step down at the end of the year.

  • Gilead Sciences snares Roche veteran O'Day as CEO
    Reutersyesterday

    Gilead Sciences snares Roche veteran O'Day as CEO

    O'Day, now head of Roche's pharmaceuticals business, joined the company in 1987 and held various roles in the United States before moving in 1998 to headquarters in Basel, Switzerland. O'Day's hiring comes about four months after Gilead said in July that Chief Executive John Milligan and Chairman John Martin would step down at the end of the year.

  • Financial Timesyesterday

    [$$] US drugmaker Gilead poaches Roche executive Daniel O’Day

    has poached pharmaceutical industry veteran Daniel O’Day from Swiss rival Roche to be its new chief executive as it battles to revive flagging sales. from Gilead was announced in July. At the same time, Gilead said its chairman John Martin would also leave.

  • GlobeNewswireyesterday

    New member proposed for election to Roche Board of Directors

    Basel, 10 December 2018 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that at its December meeting the Board of Directors (BoD) of Roche Holding Ltd decided on first proposals for approval by the ...

  • GlobeNewswireyesterday

    Changes to the Roche Corporate Executive Committee

    OTCQX: RHHBY) today announced that Daniel O`Day, CEO Roche Pharmaceuticals and member of the Corporate Executive Committee, will be stepping down from his role as of 31 December 2018. Until the end of February 2019 and prior to assuming new responsibilities outside of Roche, he will provide his support to ensure a smooth transition of activities. William (Bill) Anderson, currently CEO of Genentech, will be appointed CEO Roche Pharmaceuticals effective 1 January 2019.

  • Benzingayesterday

    What Are The Biggest International Stocks Traded Over-The-Counter?

    Investing in international companies is one of the hallmarks of building a diverse portfolio. Not only does it give investors access to key foreign markets, but it’s one of the main ways investors diversify ...

  • The Wall Street Journalyesterday

    Roche Executive Daniel O’Day Is Named Gilead CEO

    Gilead Sciences Inc. has named industry veteran Daniel O’Day to take the helm and help the drug company revive sales and recover from a disappointing deal. Mr. O’Day, whose hiring was announced early Monday, will become Gilead CEO after a long career at Switzerland’s Roche Holding AG, most recently running its pharmaceuticals group. It is the kind of experience that Gilead has been seeking since CEO John Milligan unexpectedly said in July he will leave by year’s end.

  • Benzinga4 days ago

    The Daily Biotech Pulse: FDA Nod For Roche, Bristol-Myers Hikes Dividend, 2 Biotechs To Debut

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peak (Biotech stocks hitting 52-week highs on Dec. 6) Gritstone Oncology Inc (NASDAQ: GRTS ) Down In The Dumps ...

  • Reuters4 days ago

    Roche's lung cancer combo treatment wins FDA approval

    The approval was based on results from a late-stage study, which showed the Tecentriq regimen helped patients with metastatic non-squamous non-small cell lung cancer (NSCLC) live significantly longer, compared with Avastin and chemotherapy, the company said in a statement. The drug on Wednesday had also won priority review from the U.S. regulator for treating patients with untreated extensive-stage small cell lung cancer. The drug, however, has trailed Merck's (MRK.N) Keytruda and Bristol Myers Squibb's (BMY.N) Opdivo in revenue as those medicines beat it to market in other indications.

  • Reuters4 days ago

    Roche's lung cancer combo treatment wins FDA approval

    Swiss drugmaker Roche Holding AG said on Thursday that its Tecentriq immunotherapy in combination with Avastin and chemotherapy won U.S. Food and Drug Administration approval as a first-line treatment for a type of lung cancer. The approval was based on results from a late-stage study, which showed the Tecentriq regimen helped patients with metastatic non-squamous non-small cell lung cancer (NSCLC) live significantly longer, compared with Avastin and chemotherapy, the company said in a statement. The drug on Wednesday had also won priority review from the U.S. regulator for treating patients with untreated extensive-stage small cell lung cancer.

  • GlobeNewswire4 days ago

    FDA approves Roche's Tecentriq in combination with Avastin and chemotherapy for the initial treatment of people with a specific type of metastatic lung cancer

    OTCQX: RHHBY) today announced that the US Food and Drug Administration (FDA) approved Tecentriq® (atezolizumab) in combination with Avastin® (bevacizumab), paclitaxel and carboplatin (chemotherapy), for the initial (first-line) treatment of people with metastatic non-squamous non-small cell lung cancer (NSCLC) with no EGFR or ALK genomic tumour aberrations.

  • Reuters5 days ago

    Roche's lung cancer combo treatment wins FDA approval

    Swiss drugmaker Roche Holding AG said on Thursday that its Tecentriq immunotherapy in combination with Avastin and chemotherapy was approved by the U.S. Food and Drug Administration as a first-line treatment for a type of lung cancer. The approval was based on results from a late-stage study, which showed the Tecentriq regimen helped patients with metastatic non-squamous non-small cell lung cancer live significantly longer, compared with Avastin and chemotherapy, the company said in a statement. The drug on Wednesday had also won priority review from the U.S. regulator for treating patients with untreated extensive-stage small cell lung cancer.

  • Roche's Kadcyla Halves Death Risk in Breast Cancer Study
    Zacks5 days ago

    Roche's Kadcyla Halves Death Risk in Breast Cancer Study

    Roche (RHHBY) announces detailed data from a late-stage study on Kadcyla in early breast cancer patients. Kadcyla reduces risk of disease recurrence by 50% compared to Herceptin.

  • Business Wire5 days ago

    FDA Approves Genentech’s Tecentriq in Combination With Avastin and Chemotherapy for the Initial Treatment of People With a Specific Type of Metastatic Lung Cancer

    OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) approved Tecentriq® (atezolizumab), in combination with Avastin® (bevacizumab), paclitaxel and carboplatin (chemotherapy), for the initial (first-line) treatment of people with metastatic non-squamous non-small cell lung cancer (NSCLC) with no EGFR or ALK genomic tumor aberrations.

  • AbbVie Halts Rova-T Phase III Second-Line Lung Cancer Study
    Zacks5 days ago

    AbbVie Halts Rova-T Phase III Second-Line Lung Cancer Study

    IDMC recommends AbbVie (ABBV) to stop enrolment in a late-stage study on its small cell lung cancer candidate, Rova-T.

  • Exelixis Initiates Pivotal Liver Cancer Study on Cabometyx
    Zacks5 days ago

    Exelixis Initiates Pivotal Liver Cancer Study on Cabometyx

    Exelixis (EXEL) and its partner announce initiation of a pivotal study to evaluate its kidney cancer drug, Cabometyx, in combination with Roche's Tecentriq in liver cancer.

  • J&J's Blood Cancer Drugs Succeed in Label Expansion Studies
    Zacks6 days ago

    J&J's Blood Cancer Drugs Succeed in Label Expansion Studies

    J&J (JNJ) presents positive data from late-stage studies evaluating its blood cancer drugs, Imbruvica and Darzalex, in the first-line setting at ASH.